Modern clinical guidelines for managing osteoarthritis (OA)—such as those from the American College of Rheumatology (ACR), the Arthritis Foundation, and the European Alliance of Associations for Rheumatology (EULAR)—emphasize a tiered approach (Buelt; Kolasinski et al., 2020; Moseng et al., 2024). Treatment is highly individualized and focuses first on core non-pharmacological strategies before introducing medications or surgical interventions (Kolasinski et al., 2020; Moseng et al., 2024).
The standard treatment pathway is broken down into four major categories.
1. Core Non-Pharmacological Interventions (First-Line)
Every major guideline strongly agrees that non-pharmacological core treatments should be implemented for all patients with hip, knee, or hand osteoarthritis, regardless of disease severity (Gibbs et al., 2023; Overton et al., 2022).
Structured Exercise: Regular low-impact aerobic exercise and strength/resistance training are strongly recommended (Gibbs et al., 2023; Overton et al., 2022). Options include land-based walking, aquatic therapy, stationary cycling, and mind-body exercises like Tai Chi or Yoga (Buelt; Overton et al., 2022). No single exercise type has been proven superior; choices should be based on patient preference and access (Overton et al., 2022).
Weight Management: For individuals with knee or hip osteoarthritis who are overweight or obese, losing weight is a critical first-line recommendation (Gibbs et al., 2023; Kolasinski et al., 2020). Studies show that losing even 5% of baseline body weight can significantly reduce pain and joint stress (Buelt).
Patient Education & Self-Management: Standard care requires educating the patient on the nature of OA, joint protection strategies, and pacing daily activities to build personal self-efficacy (Overton et al., 2022).
Assistive Devices: Using a cane (held in the hand opposite the affected lower-limb joint), tibiofemoral knee braces for specific alignment issues, or hand orthoses for thumb (first CMC) joint OA are strongly endorsed (Kolasinski et al., 2020).
2. Pharmacological Treatments
When core lifestyle modifications are not enough to manage pain, medical therapies are introduced. Guidelines emphasize utilizing the lowest effective dose for the shortest possible duration (Buelt).
First-Line Medications
Topical NSAIDs: Topical Non-Steroidal Anti-Inflammatory Drugs (e.g., diclofenac gel) are strongly recommended as a first-line medical option for knee and hand OA (Kolasinski et al., 2020). They provide localized pain relief with a much lower risk of systemic gastrointestinal or cardiovascular side effects compared to oral pills.
Second-Line & Adjunctive Medications
Oral NSAIDs: Strongly recommended for knee, hip, and hand OA, especially when multiple joints are involved or topical treatments fail (Buelt; Kolasinski et al., 2020). However, they carry risks of gastrointestinal bleeding, cardiovascular events, and renal toxicity, requiring careful screening for patient comorbidities.
Acetaminophen (Paracetamol): Only conditionally recommended for short-term or episodic pain relief (Buelt). Recent guidelines have downgraded its use because clinical data shows it has a very modest benefit that is often outweighed by potential liver risks when used at high doses long-term.
Duloxetine: Conditionally recommended as an adjunctive treatment, particularly for patients with multi-joint osteoarthritis or those who cannot tolerate NSAIDs (Buelt; Kolasinski et al., 2020).
Intra-articular Corticosteroid Injections: Strongly recommended for short-term, rapid pain relief during acute flare-ups of knee or hip OA (Gibbs et al., 2023; Kolasinski et al., 2020). They generally offer 4 to 8 weeks of relief but are not recommended as a long-term continuous strategy (SINUSAS).
3. Treatments Recommended Against
Recent scientific updates have explicitly advised against several traditional or popular therapies due to a lack of efficacy in high-quality trials or safety concerns:
Glucosamine and Chondroitin: Recommended against by most major medical boards (like ACR and OARSI) due to inconsistent data and lack of proven efficacy over placebos (Arden et al., 2020; Buelt).
Hyaluronic Acid Injections (Viscosupplementation): Recommended against or strongly restricted by several higher-quality guidelines for hip and knee OA, as recent large-scale reviews show minimal clinical benefit over a standard saline placebo injection (Buelt; Gibbs et al., 2023).
Platelet-Rich Plasma (PRP) & Stem Cell Injections: Explicitly recommended against across major guidelines due to a lack of standardization, mixed clinical data, and safety concerns (Buelt; Gibbs et al., 2023).
Opioids (Non-Tramadol): Strongly recommended against due to the high risk of dependency, tolerance, and systemic toxicity (Buelt).
4. Surgical Interventions
Surgical evaluation is reserved for patients with advanced, end-stage osteoarthritis who suffer from intractable pain and significant loss of physical function despite maximizing non-pharmacological and pharmacological treatments (SINUSAS).
Total Joint Arthroplasty (Joint Replacement): Highly effective and cost-efficient for end-stage knee, hip, or shoulder OA (Arden et al., 2020; SINUSAS).
Arthroscopy: Arthroscopic debridement or "cleaning out the joint" is consistently recommended against for osteoarthritis unless there is clear mechanical locking caused by a loose body or acute meniscal tear (Gibbs et al., 2023).
References
Arden, N. K., Perry, T. A., Bannuru, R. R., Bruyère, O., Cooper, C., Haugen, I. K., Hochberg, M. C., McAlindon, T. E., Mobasheri, A., & Reginster, J.-Y. (2020). Non-surgical management of knee osteoarthritis: comparison of ESCEO and OARSI 2019 guidelines. Nature Reviews Rheumatology, 17(1), 59–66. https://doi.org/10.1038/s41584-020-00523-9
Cited by: 648
Buelt, A. (2021). Osteoarthritis Management: Updated Guidelines from the American College of Rheumatology and Arthritis Foundation. American Family Physician, 103(2), 120–122.
Cited by: 38
Gibbs, A. J., Gray, B., Wallis, J. A., Taylor, N. F., Kemp, J. L., Hunter, D. J., & Barton, C. J. (2023). Recommendations for the management of hip and knee osteoarthritis: A systematic review of clinical practice guidelines. Osteoarthritis and Cartilage, 31(10), 1280–1292. https://doi.org/10.1016/j.joca.2023.05.015
Cited by: 297
Kolasinski, S. L., Neogi, T., Hochberg, M. C., Oatis, C., Guyatt, G., Block, J., Callahan, L., Copenhaver, C., Dodge, C., Felson, D., Gellar, K., Harvey, W. F., Hawker, G., Herzig, E., Kwoh, C. K., Nelson, A. E., Samuels, J., Scanzello, C., White, D., ... Ishimori, M. (2020). 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis Care & Research, 72(2), 149–162. https://doi.org/10.1002/acr.24131
Cited by: 4383
Moseng, T., Vliet Vlieland, T. P. M., Battista, S., Beckwée, D., Boyadzhieva, V., Conaghan, P. G., Costa, D., Doherty, M., Finney, A. G., Georgiev, T., Gobbo, M., Kennedy, N., Kjeken, I., Kroon, F. P. B., Lohmander, L. S., Lund, H., Mallen, C. D., Pavelka, K., Pitsillidou, I. A., ... Østerås, N. (2024). EULAR recommendations for the non-pharmacological core management of hip and knee osteoarthritis: 2023 update. Annals of the Rheumatic Diseases, 83(6), 730–740. https://doi.org/10.1136/ard-2023-225041
Cited by: 375
Overton, C., Nelson, A. E., & Neogi, T. (2022). Osteoarthritis Treatment Guidelines from Six Professional Societies. Rheumatic Disease Clinics of North America, 48(3), 637–657. https://doi.org/10.1016/j.rdc.2022.03.009
Cited by: 93
SINUSAS, K. (2012). Osteoarthritis: Diagnosis and Treatment. American Family Physician, 85(1), 49–56.
Cited by: 849